MARKET

NRBO

NRBO

NeuroBo Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.400
-0.280
-5.98%
After Hours: 4.400 0 0.00% 16:00 03/03 EST
OPEN
4.650
PREV CLOSE
4.680
HIGH
4.860
LOW
4.360
VOLUME
167.70K
TURNOVER
--
52 WEEK HIGH
29.71
52 WEEK LOW
4.120
MARKET CAP
72.28M
P/E (TTM)
-1.5882
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
AavantiBio Adds Veteran Life Sciences Executive Douglas J. Swirsky as Chief Financial Officer and Treasurer
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Douglas J. Swirsky as Chief Financial Officer and Treasurer effective February 1, 2021. A seasoned financial and...
BusinessWire · 10h ago
NeuroBo Pharmaceuticals Receives Intention To Grant Patent Today From European Patent Office Titled 'COMPOSITION CONTAINING PORIA COCOS BARK EXTRACT FOR PREVENTING, IMPROVING OR TREATING NEURODEGENERATIVE DISORDERS'
https://register.epo.org/application?number=EP19210811&tab=main
Benzinga · 1d ago
The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 23)
Benzinga · 02/24 12:30
DJ NeuroBo Pharmaceuticals Price Target Cut to $16.00/Share From $20.00 by HC Wainwright & Co.
Dow Jones · 02/01 11:34
DJ NeuroBo Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 02/01 11:34
--Analyst Actions: HC Wainwright Adjusts Price Target on NeuroBo Pharmaceuticals to $16 From $20, Reiterates Buy Rating
MT Newswires · 02/01 11:19
NeuroBo Pharmaceuticals Files Shelf for Up to 5 Million Common Shares on Behalf of Selling Stockholders
MT Newswires · 01/26 04:29
BRIEF-Neurobo Pharmaceuticals Inc Files For Stock Shelf Of Up To 5 Million Shares By Selling Stockholder - SEC Filing
reuters.com · 01/25 22:34
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NRBO. Analyze the recent business situations of NeuroBo Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NRBO stock price target is 16.00 with a high estimate of 16.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 52
Institutional Holdings: 3.46M
% Owned: 21.05%
Shares Outstanding: 16.43M
TypeInstitutionsShares
Increased
12
46.85K
New
6
64.07K
Decreased
7
83.55K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-3.96%
Pharmaceuticals & Medical Research
-1.89%
Key Executives
President/Chief Executive Officer/Chief Financial Officer/Treasurer/Secretary/Director
Jeong Gu Kang
Chairman/Director
Douglas Swirsky
President/Chief Executive Officer/Chief Financial Officer/Treasurer/Secretary/Director
jeong Gu Kang
Chief Operating Officer/Senior Vice President/Director
Akash Bakshi
Senior Vice President
Andrew Bartynski
Senior Vice President
Nadja Mannowetz
Other
Mark Versavel
Independent Director
Jason Groves
Independent Director
Jeong Gyun Oh
Independent Director
Michael Salsbury
  • Dividends
  • Splits
  • Insider Activity
No Data
About NRBO
NeuroBo Pharmaceuticals, Inc., formerly Gemphire Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on developing pharmaceuticals to treat neurodegenerative disorders. The Company is addressing unmet needs in patients with Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease. The Company’s product candidate, NB-01, is targeting neuropathic pain with an indication in PDN. The Company also provides NB-02, which is an Alzheimer’s and tauopathies drug. Its product candidate Gemcabene is focused on developing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications such as homozygous familial hypercholesterolemia (HoFH), as well as severe hypertriglyceridemia (SHTG). It also focused on developing capsule formulation of niclosamide for coronavirus indications.

Webull offers kinds of Neurobo Pharmaceuticals Inc stock information, including NASDAQ:NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NRBO stock methods without spending real money on the virtual paper trading platform.